Literature DB >> 15617473

Can tumor angiogenesis be inhibited without resistance?

Kathy D Miller1, Christopher J Sweeney, George W Sledge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15617473     DOI： 10.1007/3-7643-7311-3_7

Source DB:  PubMed          Journal:  EXS        ISSN： 1023-294X


× No keyword cloud information.
  33 in total

1.  Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.

Authors:  B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Kartik Angara; Peng Zeng; Robert A Knight; Alfonso G Scicli; Ali S Arbab
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

2.  Transforming growth factor-β is required for vasculogenic mimicry formation in glioma cell line U251MG.

Authors:  Gengqiang Ling; Shiyong Wang; Zhenhua Song; Xinlin Sun; Yijing Liu; Xiaodan Jiang; Yingqian Cai; Mouxuan Du; Yiquan Ke
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

Review 3.  Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.

Authors:  Peter A Cohen; Jennifer S Ko; Walter J Storkus; Christopher D Spencer; Judy M Bradley; Jessica E Gorman; Dustin B McCurry; Soroya Zorro-Manrique; Anna Lucia Dominguez; Latha B Pathangey; Patricia A Rayman; Brian I Rini; Sandra J Gendler; James H Finke
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

4.  Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.

Authors:  Kartik Angara; Mohammad H Rashid; Adarsh Shankar; Roxan Ara; Asm Iskander; Thaiz F Borin; Meenu Jain; Bhagelu R Achyut; Ali S Arbab
Journal:  Histol Histopathol       Date:  2016-12-19       Impact factor: 2.303

5.  Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study.

Authors:  Meser M Ali; Sanath Kumar; Adarsh Shankar; Nadimpalli R S Varma; A S M Iskander; Branislava Janic; Wilson B Chwang; Rajan Jain; Abbas Babajeni-Feremi; Thaiz F Borin; Hassan Bagher-Ebadian; Stephen L Brown; James R Ewing; Ali S Arbab
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

Review 6.  Myeloid-derived suppressor cells: a novel therapeutic target.

Authors:  Jennifer S Ko; Ronald M Bukowski; James H Fincke
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

7.  Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.

Authors:  Ruman Rahman; Stuart Smith; Cheryl Rahman; Richard Grundy
Journal:  J Oncol       Date:  2010-04-11       Impact factor: 4.375

8.  Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.

Authors:  B R Achyut; Adarsh Shankar; A S M Iskander; Roxan Ara; Robert A Knight; Alfonso G Scicli; Ali S Arbab
Journal:  Cancer Biol Ther       Date:  2016-01-21       Impact factor: 4.742

Review 9.  Modes of resistance to anti-angiogenic therapy.

Authors:  Gabriele Bergers; Douglas Hanahan
Journal:  Nat Rev Cancer       Date:  2008-08       Impact factor: 60.716

10.  VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2.

Authors:  Z Zhang; K G Neiva; M W Lingen; L M Ellis; J E Nör
Journal:  Cell Death Differ       Date:  2009-10-16       Impact factor: 15.828
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.